Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064034 | 0.90 | CYP1A2 (0.68) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL12584223 | 0.87 | LMNA (0.71) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL10113976 | 0.86 | LMNA (0.70) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL10113992 | 0.86 | LMNA (0.79) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL10113880 | 0.85 | TRPA1 (0.72) | KMT2AMEN1CYP1A2RXFP1TP53 | |
| SCHEMBL10114496 | 0.84 | MAPT (0.71) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL14754446 | 0.83 | LMNA (0.65) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL20161634 | 0.82 | LMNA (0.68) | LMNAGAAMAPK1KMT2AMEN1 | |
| SCHEMBL20561142 | 0.81 | LMNA (0.73) | LMNAMAPK1RXFP1TP53ADORA2B | |
| SCHEMBL10131426 | 0.80 | CYP1A2 (0.68) | LMNAGAAMAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | LMNA 1619/4885GAA 876/4885MAPK1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.